Cargando…
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS
Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily...
Autores principales: | Jerath, Angela, Ferguson, Niall D., Cuthbertson, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315695/ https://www.ncbi.nlm.nih.gov/pubmed/32588067 http://dx.doi.org/10.1007/s00134-020-06154-8 |
Ejemplares similares
-
Current and evolving standards of care for patients with ARDS
por: Menk, Mario, et al.
Publicado: (2020) -
Emerging pharmacological therapies for ARDS: COVID-19 and beyond
por: Horie, Shahd, et al.
Publicado: (2020) -
Pulmonary infections complicating ARDS
por: Luyt, Charles-Edouard, et al.
Publicado: (2020) -
Reflections on palliative sedation
por: Twycross, Robert
Publicado: (2019) -
Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies
por: Ware, Lorraine B., et al.
Publicado: (2020)